Ch. 31 Inflammatory CNS Disorders Flashcards
Inflammatory brain disorders that primarily affect the white matter
1) MS
2) Neuromyelitis optica spectrum disorders
Rheumatic disorders with secondary involvement of the CNS
1) NP SLE
2) APAS
3) Neuro-Behcet
4) Neurosarcoidosis
Important infectious causes of encephalitis, symptoms and imaging findings of which may overlap with idiopathic inflammatory brain disorders
1) Mycoplasma
2) Influenza A
3) Parainfluenza
4) Enterovirus
5) EBV
6) VZV
7) CMV
8) HSV
Inflammatory brain disorders
Table 31.1 (p.440)
Clinical manifestations of optic neuritis in inflammatory brain disorders
1) Reduced visual acuity
2) Enlarged blind spot or central scotoma
3) Pain with ocular movements
4) Red-green color desaturation
Clinical manifestations of spinal cord lesions in inflammatory brain disorders
1) Motor impairment/s
2) Sensory loss (with a localized sensory level)
3) Bowel and bladder impairment
4) Pain with neck flexion (Lhermitte symptom)
Clinical manifestations of brainstem inflammation in inflammatory brain disorders
1) Internuclear ophthalmoplegia
2) Hypersomnolence (d/t diencephalic involvement
3) Hiccups
4) Hyperphagia
Clinical manifestations of cerebellar involvement in inflammatory brain disorders
1) Impaired gait balance
2) Dysmetria
3) Dysarthria
4) Impairment of rapid alternating movements
Clinical manifestations of cerebral lesions in inflammatory brain disorders
1) Focal motor or sensory deficits
2) Encephalopathy
Clinical manifestations of cortical lesions in inflammatory brain disorders
Seizures
Clinical manifestations of basal ganglia involvement in inflammatory brain disorders
1) Dystonia
2) Catatonia
NMDA receptor encephalitis and other autoimmune encephalopathies characteristically affect this structure of the CNS
Basal ganglia
T/F Most inflammatory brain disorders begin with an acute attack
T
Antibodies that identify children with neuromyelitis optica spectrum disorder (NMOSD)
Antibodies directed against astrocytic water channel aquaporin 4 (AQP4)
Antibodies common in children with ADEM and in children with AQP4-negative NMOSD
Antibodies against myelin oligodendrocyte glycoprotein (MOG)